Posted by Michael Wonder on 29 Apr 2021
EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen
29 April 2021 - EMA has started evaluating an application to extend the use of Olumiant (baricitinib) to include treatment of COVID-19 in hospitalised patients from 10 years of age who require supplemental oxygen.
Olumiant is an immunosuppressant (a medicine that reduces the activity of the immune system). It is currently authorised for use in adults with moderate to severe rheumatoid arthritis or atopic dermatitis (eczema). Its active substance, baricitinib, blocks the action of enzymes called Janus kinases that play an important role in immune processes that lead to inflammation. It is thought that this could also help reduce the inflammation and tissue damage associated with severe COVID-19 infection.
